Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Aplenzin, Budeprion SR,Forfivo XL, Buproban, Wellbutrin SR, Wellbutrin XL, Zyban
Synonyms :
bupropion
Class :
Antidepressants and antianxiety drugs; Atypical antidepressants
Brand Name :
Aplenzin, Budeprion SR,Forfivo XL, Buproban, Wellbutrin SR, Wellbutrin XL, Zyban
Synonyms :
bupropion
Class :
Antidepressants and antianxiety drugs; Atypical antidepressants
Dosage Forms & Strengths
Adult
Tablet
75 mg
100 mg
Tablet (Sustained release)
100 mg
150 mg
200 mg
Tablet (extended release)
150 mg
300 mg
450 mg
150
mg
Tablet
Orally
once a day
3
days
15 - 45
mg
Tablet
Orally
Once a day in the night
Immediate release tablet-
100 mg orally every 12 hours. Increase the dose to 100 mg every 8 hours. If no clinical improvement is seen, maximize the dose up to 150 mg every 8 hours.
Sustained release tablet-
150 mg orally each day. Increase the dose to 150 mg every 12 hours. If no clinical improvement is seen, maximize the dose up to 150 mg every 12 hours.
Extended-release tablet-
150 mg orally each day. Increase the dose to 450 mg each day. If no clinical improvement is seen, maximize the dose up to 300 mg each day.
Aplenzin-
174 mg orally each day. Increase the dose after 4 days, to 348 mg. Do not increase the dose to more than 522 mg each day.
Forfivo XL-
450 mg orally each day
Can be utilized in patients who already are receiving 300 mg/day of bupropion
Immediate release tablet-
100 mg orally every 12 hours. Increase the dose to 100 mg every 8 hours. If no clinical improvement is seen, maximize the dose up to 150 mg every 8 hours.
Sustained release tablet-
150 mg orally each day. Increase the dose to 150 mg every 12 hours. If no clinical improvement is seen, maximize the dose up to 150 mg every 12 hours.
Extended-release tablet-
150 mg orally each day. Increase the dose to 450 mg each day. If no clinical improvement is seen, maximize the dose up to 300 mg each day.
Aplenzin-
174 mg orally each day. Increase the dose after 4 days, to 348 mg. Do not increase the dose to more than 522 mg each day.
Forfivo XL-
450 mg orally each day
Can be utilized in patients who already are receiving 300 mg/day of bupropion
Immediate-release tablet-
100 mg orally every 12 hours
Increase the dose to 100 mg every 8 hours
If no clinical improvement is seen, maximize the dose up to 150 mg every 8 hours
Sustained release tablet-
150 mg orally each day
Increase the dose to 150 mg every 12 hours
If no clinical improvement is seen, maximize the dose up to 150 mg every 12 hours
Extended-release tablet-
150 mg orally each day
Increase the dose to 150 mg every 12 hours after 3 weeks
If no clinical improvement is seen, maximize the dose by up to 300 mg each day
Aplenzin-
174 mg orally each day
Increase the dose after 4 days to 348 mg
Do not increase the dose to more than 522 mg each day
Forfivo XL-
450 mg orally each day
It can be utilized in patients who already are receiving 300 mg/day of bupropion
150 mg orally each day for 3 days
Increase the dose to 150 mg every 12 hours
Continue the treatment for up to 7-12 weeks
If successful quit occurs after 7-12 weeks, consider a maintenance therapy
Indicated for neuropathic pain
150 mg sustained-release bupropion orally twice daily for 6 weeks
Attention-deficit/hyperactivity Disorder (ADHD)
Initially, 150 mg/day orally
Standardize to 150-450 mg/day based on efficacy and tolerability
Administer as sustained or extended-release formulations
Tablet
75 mg
100 mg
Tablet (Sustained release)
100 mg
150 mg
200 mg
Tablet (extended release)
150 mg
300 mg
450 mg
Attention-deficit/hyperactivity Disorder (ADHD)
150
mg
Tablet
Orally
once a day
Attention-deficit/hyperactivity Disorder (ADHD)
(Off-Label)
Immediate-release
Initially, 3 mg/kg per day or 150 mg/day orally
Standardize to 6 mg/kg/day or a maximum of 300 mg each day
Do not exceed more than 150 mg
Extended-Release
Initially, 3 mg/kg per day or 150 mg/day orally
Standardize to 6 mg/kg/day or a maximum of 300 mg each day
Sustained-Release
Initially, 3 mg/kg per day or 150 mg/day orally
Standardize to 6 mg/kg/day or a maximum of 300 mg each day
Refer adult dosing
The risk of seizure may be increased.
it increases the effect of hypertension of bupropion
CYP2D6 Inhibitors increase the concentration of doxorubicin in serum
when both drugs are combined, there may be an increased risk of seizures
it increases the toxicity of norepinephrine reuptake inhibitors
Norepinephrine Reuptake Inhibitors increase arrhythmia, causing the effect of dronedarone
it increases the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
it increases the effect of Norepinephrine Reuptake Inhibitors
it increases the toxicity of norepinephrine reuptake inhibitors
Norepinephrine Reuptake Inhibitors increase arrhythmia, causing the effect of dronedarone
it increases the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
it increases the effect of Norepinephrine Reuptake Inhibitors
it increases the toxicity of norepinephrine reuptake inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
bupropion increases the toxicity of vilazodone
CYP2D6 Inhibitors increase the concentration of tamsulosin in serum
It may enhance the toxicity when combined with mipomersen
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
it may diminish the metabolism when combined with diosmin
Combining bupropion with pranlukast may cause a reduction in the bupropion’s metabolism
The potential for increased CNS depression risk or seriousness occurs when bupropion is used together with pipecuronium
When bupropion is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
bupropion has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
When captodiame is used together with bupropion, There is a risk or seriousness of CNS depression is enhanced
When bupropion is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when bupropion is used together with fencamfamin
When bupropion is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When bupropion is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
When domeperidone and bupropion is used together, this leads to reduction in the domeperidone’s metabolism
When bupropion is used together with fluconazole, this leads to reduction in the bupropion metabolism
When chlordiazepoxide is used together with bupropion, this leads to enhanced risk or seriousness of CNS depression
bupropion: they may enhance the serum concentration of CYP2D6 Inhibitors
bupropion: they may enhance the serum concentration of CYP2D6 Inhibitors
bupropion: they may enhance the serum concentration of CYP2D6 Inhibitors
bupropion: they may enhance the serum concentration of CYP2D6 Inhibitors
bupropion: they may enhance the serum concentration of CYP2D6 Inhibitors
side effects of bupropion are increased when dopamine agonist is combined
side effects of bupropion are increased when dopamine agonist is combined
side effects of bupropion are increased when dopamine agonist is combined
side effects of bupropion are increased when dopamine agonist is combined
side effects of bupropion are increased when dopamine agonist is combined
When emylcamate is used together with bupropion, this leads to enhanced risk or seriousness of CNS depression
When bupropion is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
bupropion : it may increase the toxic effect of Methemoglobinemia Associated Agents
bupropion : it may increase the toxic effect of Methemoglobinemia Associated Agents
bupropion : it may increase the toxic effect of Methemoglobinemia Associated Agents
bupropion : it may increase the toxic effect of Methemoglobinemia Associated Agents
bupropion : it may increase the toxic effect of Methemoglobinemia Associated Agents
When acepromazine is used together with bupropion, this leads to enhanced risk or seriousness of CNS depression
bupropion leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefpirome leads to a reduction in the rate of excretion of bupropion which leads to increased level of serum
bupropion leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
bupropion leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
bupropion leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
bupropion leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
When bupropion is used together with profenamine, this leads to enhanced risk or seriousness of adverse events
bupropion may decrease the excretion rate of almasilate, leading to higher serum levels
If combined with pizotifen it may increase the neuroexcitatory or seizure-potentiating effect of bupropion
it increases the concentration of Norepinephrine Reuptake Inhibitors
it increases the toxicity of Norepinephrine Reuptake Inhibitors
norepinephrine reuptake inhibitors decrease the effect of guanethidine
it increases the concentration of Norepinephrine Reuptake Inhibitors
it increases the toxicity of Norepinephrine Reuptake Inhibitors
norepinephrine reuptake inhibitors decrease the effect of guanethidine
bupropion when combined with sibutramine can enhance the risk of causing seizures
toxicity of bupropion may be increased with caffeine
the rate of excretion of aurothioglucose may be reduced with bupropion
bupropion might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
it increases the effect of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
it increases the effect of norepinephrine reuptake inhibitors
Action and Spectrum:
Bupropion increases norepinephrine and dopamine levels in the brain which stops their reuptake into neurons.
Adverse reaction:
>10%
Weight loss
Insomnia
Dizziness
Dry mouth
Nausea
Headache
Pharyngitis
1-10%
Infection
Abdominal pain
Anxiety
Tinnitus
Tremor
Nervousness
Pruritus
Vomiting
Decreased memory
Irritability
Somnolence
Sinusitis
Weight gain
Arthritis
Fever
Twitch
Frequency Not Defined
Confusion
Erythema
Ataxia
Cystitis
Coma
Gastric reflux
Post marketing reports
Hyperglycemia
Inappropriate antidiuretic hormone secretion
Hyponatremia
Black box warning:
None
Contraindications/caution:
Hypersensitivity
Seizure disorders
Liver and kidney disease
Cardiovascular disease
Psychiatric disorders
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Pharmacology:
It acts as NDRI which blocks reuptake of norepinephrine and dopamine into presynaptic neuron, and it affects neurotransmitter levels.
Bupropion’s antagonist activity at nicotinic receptors helps to quit smoking.
Pharmacodynamics:
Bupropion blocks norepinephrine and dopamine reuptake, which increases their levels in the synapse and their effects on the post-synaptic neuron.
Pharmacokinetics:
Absorption
The peak serum is achieved within 2 hours for immediate-release and 3 hours for extended-release.
Distribution
The volume of distribution is 20 to 47 L/kg.
Metabolism
It undergoes hepatic metabolism.
Elimination and Excretion
It is excreted through urine and feces.
Administration:
It is taken orally in tablet form.
Patient information leaflet:
Generic Name: Bupropion
Why do we use Bupropion?
Bupropion is indicated in treatment of major depressive disorder.
It is used in the treatment of attention deficit/hyperactivity disorder and seasonal affective disorder.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
